Tonix Pharmaceuticals Holding Stock EBITDA
| TNXP Stock | USD 0.19 0.0005 0.26% |
Tonix Pharmaceuticals Holding fundamentals help investors to digest information that contributes to Tonix Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Tonix Stock. The fundamental analysis module provides a way to measure Tonix Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tonix Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -114.1 M | -108.4 M |
Tonix | EBITDA |
Tonix Pharmaceuticals Holding Company EBITDA Analysis
Tonix Pharmaceuticals' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Tonix Pharmaceuticals EBITDA | (114.09 M) |
Most of Tonix Pharmaceuticals' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tonix Pharmaceuticals Holding is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Tonix EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Tonix Pharmaceuticals is extremely important. It helps to project a fair market value of Tonix Stock properly, considering its historical fundamentals such as EBITDA. Since Tonix Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Tonix Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Tonix Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Tonix Ebitda
According to the company disclosure, Tonix Pharmaceuticals Holding reported earnings before interest,tax, depreciation and amortization of (114.09 Million). This is 113.0% lower than that of the Biotechnology sector and 213.91% lower than that of the Health Care industry. The ebitda for all United States stocks is 102.93% higher than that of the company.
Tonix EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tonix Pharmaceuticals' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tonix Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Tonix Pharmaceuticals by comparing valuation metrics of similar companies.Tonix Pharmaceuticals is currently under evaluation in ebitda category among its peers.
Tonix Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Tonix Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Tonix Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Tonix Pharmaceuticals' value.| Shares | Ubs Group Ag | 2024-06-30 | 50.0 | Bank Of America Corp | 2024-06-30 | 28.0 | Bnp Paribas Arbitrage, Sa | 2024-06-30 | 10.0 | Jpmorgan Chase & Co | 2024-06-30 | 9.0 | Hanson Mcclain Inc | 2024-09-30 | 7.0 | Guaranty Trust Company Of Missouri | 2024-09-30 | 7.0 | Planning Capital Management Corp | 2024-09-30 | 7.0 | Royal Bank Of Canada | 2024-06-30 | 4.0 | Global Retirement Partners, Llc. | 2024-09-30 | 2.0 | Geode Capital Management, Llc | 2024-09-30 | 116 K | Wedbush Morgan Securities Inc | 2024-09-30 | 40.5 K |
Tonix Fundamentals
| Return On Equity | -1.63 | ||||
| Return On Asset | -0.52 | ||||
| Operating Margin | (8.31) % | ||||
| Current Valuation | 15.74 M | ||||
| Shares Outstanding | 186.89 M | ||||
| Shares Owned By Insiders | 0.16 % | ||||
| Shares Owned By Institutions | 0.23 % | ||||
| Number Of Shares Shorted | 7.67 M | ||||
| Price To Earning | (0.69) X | ||||
| Price To Book | 0.48 X | ||||
| Price To Sales | 2.83 X | ||||
| Revenue | 7.77 M | ||||
| EBITDA | (114.09 M) | ||||
| Net Income | (116.66 M) | ||||
| Cash And Equivalents | 145.48 M | ||||
| Cash Per Share | 3.38 X | ||||
| Total Debt | 9.81 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 12.05 X | ||||
| Book Value Per Share | 57.61 X | ||||
| Cash Flow From Operations | (102 M) | ||||
| Short Ratio | 0.35 X | ||||
| Earnings Per Share | (80.39) X | ||||
| Target Price | 21.0 | ||||
| Number Of Employees | 103 | ||||
| Beta | 2.08 | ||||
| Market Capitalization | 35.29 M | ||||
| Total Asset | 154.46 M | ||||
| Retained Earnings | (600.66 M) | ||||
| Working Capital | 28.88 M | ||||
| Current Asset | 46.36 M | ||||
| Current Liabilities | 6.65 M | ||||
| Net Asset | 154.46 M |
About Tonix Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tonix Pharmaceuticals Holding's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tonix Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tonix Pharmaceuticals Holding based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Tonix Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tonix Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tonix Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Tonix Stock
The ability to find closely correlated positions to Tonix Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tonix Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tonix Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tonix Pharmaceuticals Holding to buy it.
The correlation of Tonix Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tonix Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tonix Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Tonix Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Tonix Stock Analysis
When running Tonix Pharmaceuticals' price analysis, check to measure Tonix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tonix Pharmaceuticals is operating at the current time. Most of Tonix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tonix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tonix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tonix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.